This session will focus on the longevity and maturing of the therapeutics field, growing interest in biopharma by investors in the diseases of aging framework and approaches, and shift from the aspirational preventative approaches to more pragmatic disease-based drug development and tractable clinical trial designs. Additionally, panelists will discuss the evolution across key geographies, with respect to therapeutic areas and across modalities.